OBJECTIVES: Pharmacogenetic testing as a means of guiding treatment decisions is beginning to see wider clinical use in psychiatry. The utility of this genetic information as it pertains to clinical decision making, treatment effectiveness, cost savings, and patient perception has not been fully characterized. STUDY DESIGN: In this retrospective study, we examined health claims data in order to assess medication adherence rates and healthcare costs for psychiatric patients. METHODS: Individuals for whom pharmacogenetic testing was ordered (cases) were contrasted with those who did not undergo such testing (controls). Cases and controls were propensity score matched in order to minimize risk of confounding in this nonrandomized study. An initial analysis of 111 cases and 222 controls examined both adherence and healthcare costs. A replication study of 116 cases and 232 controls examined adherence alone, as cost data was not available for this latter cohort. RESULTS: Overall, individuals with assay-guided treatment were significantly more medication adherent (P = 1.56 3 10–3; Cohen’s d = 0.511) than patients with standard treatment and demonstrated a relative cost savings of 9.5% in outpatient costs over a 4-month follow-up period, or $562 in total savings. CONCLUSIONS: The data show the utility of pharmacogenetic testing in everyday psychiatric clinical practice, as it can lead to improved patient adherence and decreased healthcare costs.
OBJECTIVES: Pharmacogenetic testing as a means of guiding treatment decisions is beginning to see wider clinical use in psychiatry. The utility of this genetic information as it pertains to clinical decision making, treatment effectiveness, cost savings, and patient perception has not been fully characterized. STUDY DESIGN: In this retrospective study, we examined health claims data in order to assess medication adherence rates and healthcare costs for psychiatricpatients. METHODS: Individuals for whom pharmacogenetic testing was ordered (cases) were contrasted with those who did not undergo such testing (controls). Cases and controls were propensity score matched in order to minimize risk of confounding in this nonrandomized study. An initial analysis of 111 cases and 222 controls examined both adherence and healthcare costs. A replication study of 116 cases and 232 controls examined adherence alone, as cost data was not available for this latter cohort. RESULTS: Overall, individuals with assay-guided treatment were significantly more medication adherent (P = 1.56 3 10–3; Cohen’s d = 0.511) than patients with standard treatment and demonstrated a relative cost savings of 9.5% in outpatient costs over a 4-month follow-up period, or $562 in total savings. CONCLUSIONS: The data show the utility of pharmacogenetic testing in everyday psychiatric clinical practice, as it can lead to improved patient adherence and decreased healthcare costs.
Authors: Naveen L Pereira; Derek So; Jang-Ho Bae; Ivan Chavez; Myung Ho Jeong; Sang Wook Kim; Mina Madan; John Graham; Fearghas O'Cochlain; Nicole Pauley; Ryan J Lennon; Kent Bailey; Ahmed Hasan; Linnea M Baudhuin; Malcolm R Bell; Amir Lerman; Shaun Goodman; Verghese Mathew; Michael Farkouh; Charanjit S Rihal Journal: Pharmacogenet Genomics Date: 2019-06 Impact factor: 2.089
Authors: Francis X Brennan; Kathryn R Gardner; Jay Lombard; Roy H Perlis; Maurizio Fava; Herbert W Harris; Rachel Scott Journal: Prim Care Companion CNS Disord Date: 2015-04-16
Authors: Zane Zeier; Linda L Carpenter; Ned H Kalin; Carolyn I Rodriguez; William M McDonald; Alik S Widge; Charles B Nemeroff Journal: Am J Psychiatry Date: 2018-04-25 Impact factor: 18.112
Authors: Benjamin Laplace; Benjamin Calvet; Aurelie Lacroix; Stephane Mouchabac; Nicolas Picard; Murielle Girard; Eric Charles Journal: J Pers Med Date: 2021-05-21